Tag: glomerulonephritis market share

  • Glomerulonephritis Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

    Glomerulonephritis Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

    Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

    What is the Projected CAGR for the Glomerulonephritis Market Size from 2025 to 2034?

    The market size for glomerulonephritis has seen considerable growth in recent times. The market is set to expand from $11.06 billion in 2024 to $11.64 billion in 2025, indicating a compound annual growth rate (CAGR) of 5.3%. Historic period growth has been driven by a surge in kidney disorders, the rise in post-streptococcal glomerulonephritis infections, an upswing in research and development and an increase in kidney failure incidence. Growing awareness about kidney diseases is also contributing to this growth.

    Robust expansion is predicted for the glomerulonephritis market in the upcoming years, escalating to $14.14 billion by 2029 with a compound annual growth rate (CAGR) of 5.0%. The anticipated growth during this period is attributed to factors such as rising instances of diabetes, an aged population, increased healthcare spending, a growing number of dialysis patients, and an escalation in autoimmune disease cases. Key trend projections for this period comprise the introduction of new treatments and therapy methods, advancements in diagnostic technology, innovative therapeutics and treatments, inter-company collaboration, and intravenous immunoglobulin therapy.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21193&type=smp

    How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the Glomerulonephritis Market?

    The growth of the glomerulonephritis market is anticipated to be fueled by the escalating incidences of kidney disorders. Kidney disorders encompass a spectrum of conditions that impact the kidneys’ structure or function, resulting in hindered filtration, waste elimination, and fluid regulation. The escalating incidences of kidney disorders can be attributed to factors like aging demographics, increasing instances of chronic ailments such as diabetes and hypertension, and lifestyle decisions. Kidney disorders spur glomerulonephritis by instigating disorders of the immune system, persistent inflammation, or structural harm, culminating in disrupted kidney filtration and performance. For example, the Australian Institute of Health and Welfare, a government agency based in Australia, revealed in December 2024 that mortality rates from chronic kidney disease (CKD) surged by 4.2% in 2021 and 6.2% in 2022. For the year 2021-22, nearly 2 million hospitalizations were attributed to CKD, accounting for 18% of all hospitalizations in Australia. Therefore, the escalating incidences of kidney disorders are anticipated to bolster the growth of the glomerulonephritis market.

    Which Segments in the Glomerulonephritis Offer the Most Growth?

    The glomerulonephritis market covered in this report is segmented –

    1) By Type: Acute Glomerulonephritis, Chronic Glomerulonephritis

    2) By Diagnosis: Urine And Blood Tests, Imaging Tests, Kidney Biopsy, Other Diagnosis

    3) By Treatment: Medication, Surgery, Dialysis, Other Treatments

    4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

    5) By End-User: Hospitals, Specialty Clinics, Other End-Users

    Subsegments:

    1) By Acute Glomerulonephritis: Post-infectious Glomerulonephritis, IgA Nephropathy, Lupus Nephritis, Rapidly Progressive Glomerulonephritis (RPGN), Goodpasture Syndrome

    2) By Chronic Glomerulonephritis: Focal Segmental Glomerulosclerosis (FSGS), Membranous Nephropathy, Minimal Change Disease, Alport Syndrome, Diabetic Nephropathy, Hypertensive Nephrosclerosis

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=21193&type=smp

    What Are the Fastest-Growing Geographies in the How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the Glomerulonephritis Market? Market?

    North America was the largest region in the glomerulonephritis market in 2024. The regions covered in the glomerulonephritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    What Are the Current Market Growth and Trends in the Glomerulonephritis Industry?

    Significant players in the glomerulonephritis market are dedicating efforts towards the creation of progressive non-immunosuppressive solutions. This is in response to the unfulfilled medical needs and in pursuit of enhancing patient experiences. These non-immunosuppressive solutions represent therapies that neither suppress nor weaken the immune system, with the aim to manage conditions without negatively impacting the immune functions. For example, in September 2024, FILSPARI (sparsentan) was launched by US-based biopharmaceutical company, Travere Therapeutics Inc. This drug, having received FDA approval, is intended for treating IgA nephropathy, a type of kidney disease. Being the only non-immunosuppressive therapy proven to notably slow down kidney function deterioration in patients, FILSPARI’s approval is a monumental milestone in the treatment of IgA nephropathy. This is significant as IgA nephropathy is the most prevalent form of primary glomerulonephritis. This therapy extends an innovative choice for patients who previously had limited options. This progress demonstrates Travere Therapeutics Inc.’s dedication to enhancing patient experiences in kidney disease.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/glomerulonephritis-global-market-report

    What Are the Key Elements That Define the Glomerulonephritis Market?

    Glomerulonephritis is a kidney disorder characterized by inflammation of the glomeruli, the tiny filters in the kidneys that remove waste and excess fluids from the blood. It can result from infections, autoimmune diseases, or other underlying conditions, leading to symptoms such as blood in urine, proteinuria, and swelling. If left untreated, it may progress to chronic kidney disease or kidney failure.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21193

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Glomerulonephritis Market Growth and Trends: Key Insights into Market Opportunities for 2025-2034

    Glomerulonephritis Market Growth and Trends: Key Insights into Market Opportunities for 2025-2034

    2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

    How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theGlomerulonephritis Market?

    The growing prevalence of kidney disorders is projected to propel the glomerulonephritis market. Kidney disorders are conditions that affect the kidneys’ structure or function, leading to impaired filtration, waste removal, and fluid balance. The rise in kidney disorders is due to factors such as an aging population, increasing chronic disease rates (like diabetes and hypertension), and lifestyle factors. Kidney disorders contribute to glomerulonephritis by triggering immune system dysfunction, chronic inflammation, or structural damage, which in turn impairs kidney function. For example, in December 2024, the Australian Institute of Health and Welfare reported that chronic kidney disease (CKD) mortality rates rose by 4.2% in 2021 and 6.2% in 2022. In the 2021–22 period, CKD was involved in approximately 2 million hospitalizations, accounting for 18% of all hospital admissions in Australia. Therefore, the growing prevalence of kidney disorders will drive the growth of the glomerulonephritis market.

    Get Your Free Sample Report Now – Explore Exclusive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21193&type=smp

    #What is the Projected CAGR for the Glomerulonephritis Market Size from 2025 to 2034?

    The glomerulonephritis market has experienced strong growth, increasing from $11.06 billion in 2024 to $11.64 billion in 2025 at a CAGR of 5.3%. Growth factors include a rising prevalence of kidney disorders, increased cases of infections like post-streptococcal glomerulonephritis, greater investment in R&D, a rise in kidney failure cases, and improved awareness of kidney diseases.

    The glomerulonephritis market is expected to grow steadily, reaching $14.14 billion by 2029 at a CAGR of 5.0%. Factors driving this growth include increasing cases of diabetes, an aging population, higher healthcare investments, a growing number of dialysis patients, and a rise in autoimmune diseases. Notable trends include the introduction of new treatments and therapies, advancements in diagnostic technologies, development of novel therapeutics, strategic collaborations between companies, and the adoption of intravenous immunoglobulin therapy.

    You can Directly Purchase the Report Here:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21193

    What Are the Current Market Growth and Trends in theGlomerulonephritis Market That Industry Players Should Watch?

    In the glomerulonephritis market, companies are developing non-immunosuppressive treatments to treat kidney diseases without compromising immune function. One such treatment, FILSPARI (sparsentan), was introduced by Travere Therapeutics Inc., a US-based biopharmaceutical company, in September 2024. The FDA-approved drug is designed to treat IgA nephropathy, a kidney disease, and has shown significant promise in slowing the progression of kidney function decline, offering a non-immunosuppressive option for patients who previously had limited treatments.

    What Are the Major Market Players Making an Impact on theGlomerulonephritis Market Growth?

    Major companies operating in the glomerulonephritis market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Asahi Kasei Medical Co. Ltd., Boehringer Ingelheim International GmbH, DaVita Inc., Biogen Inc., Merit Medical Systems Inc., Apellis Pharmaceuticals Inc., MorphoSys AG, Travere Therapeutics Inc., Vera Therapeutics Inc., Calliditas Therapeutics AB, Omeros Corporation, Otsuka Pharmaceutical Co. Ltd., Aurinia Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., NovelMed Therapeutics Inc.

    Order Your Report Now For A Swift Delivery:

    https://www.thebusinessresearchcompany.com/report/glomerulonephritis-global-market-report

    How Are the Key Segments of the Glomerulonephritis Market Driving Opportunities and Innovations?

    The glomerulonephritis market covered in this report is segmented –

    1) By Type: Acute Glomerulonephritis, Chronic Glomerulonephritis

    2) By Diagnosis: Urine And Blood Tests, Imaging Tests, Kidney Biopsy, Other Diagnosis

    3) By Treatment: Medication, Surgery, Dialysis, Other Treatments

    4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

    5) By End-User: Hospitals, Specialty Clinics, Other End-Users

    Subsegments:

    1) By Acute Glomerulonephritis: Post-infectious Glomerulonephritis, IgA Nephropathy, Lupus Nephritis, Rapidly Progressive Glomerulonephritis (RPGN), Goodpasture Syndrome

    2) By Chronic Glomerulonephritis: Focal Segmental Glomerulosclerosis (FSGS), Membranous Nephropathy, Minimal Change Disease, Alport Syndrome, Diabetic Nephropathy, Hypertensive Nephrosclerosis

    Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

    https://www.thebusinessresearchcompany.com/customise?id=21193&type=smp

    What Regions Are At the Forefront of #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theGlomerulonephritis Market?# Market Expansion?

    North America was the largest region in the glomerulonephritis market in 2024. The regions covered in the glomerulonephritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Browse Through More Reports Similar to the Global Glomerulonephritis Market 2025, By The Business Research Company:

    Suture Laparoscopic Forceps Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/suture-laparoscopic-forceps-global-market-report

    Electrocautery Enhanced Delivery System Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/electrocautery-enhanced-delivery-system-global-market-report

    Anemia and Other Blood Disorder Drugs Global Market Report 2025

    https://thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • In-Depth Insights into the Glomerulonephritis Market: Growth, Trends, and Opportunities for 2025-2034

    In-Depth Insights into the Glomerulonephritis Market: Growth, Trends, and Opportunities for 2025-2034

    Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

    How has the glomerulonephritis market size evolved in recent years?

    In recent times, the glomerulonephritis market has experienced substantial growth. The market size, which stood at $11.06 billion in 2024, is projected to climb to $11.64 billion in 2025, registering a compound annual growth rate (CAGR) of 5.3%. The growth of the market in the historic period is attributed to factors such as the increasing cases of kidney disorders, widespread infections like post-streptococcal glomerulonephritis, advancement in research and development, the surge in kidney failure incidents, and heightened awareness related to kidney diseases.

    What are the predictions for the glomerulonephritis market size in the coming years?

    Anticipating robust expansion in the upcoming years, the glomerulonephritis market size is predicted to reach $14.14 billion by 2029, with a compound annual growth rate (CAGR) of 5.0%. The forecast period’s escalation can be attributed to a rise in diabetes cases, a burgeoning elderly population, an escalation in healthcare expenditure, a surge in dialysis patients, and an uptick in autoimmune diseases. The emerging trends within the predicted period encompass the introduction of novel treatments and therapies, enhancements in diagnostic technologies, new therapeutics, partnerships among corporations, and the application of intravenous immunoglobulin therapy.

    Get your glomerulonephritis market report here!

    https://www.thebusinessresearchcompany.com/report/glomerulonephritis-global-market-report

    What key factors are fueling the growth of the glomerulonephritis market?

    The glomerulonephritis market is set to grow as a result of the increasing incidence of kidney disorders. Conditions which adversely affect the structure or functionality of kidneys, leading to compromised waste removal, filtration, and fluid balance, are referred to as kidney disorders. Factors paving the way to their increasing occurrence include aging demographics, escalated instances of chronic illnesses such as hypertension and diabetes, and lifestyle decisions. The role of kidney disorders in triggering glomerulonephritis includes chronic inflammation, immune system malfunction, or structural damage, which then leads to impaired kidney filtration. For instance, the Australian Institute of Health and Welfare, a government agency based in Australia, stated in December 2024 that chronic kidney disease (CKD) mortality rates had grown by 4.2% in 2021 and 6.2% in 2022. CKD was implicated in roughly 2 million hospital admissions in 2021-22, accounting for 18% of all Australia’s hospitalizations. Thus, the growing frequency of kidney disorders is likely to fuel the expansion of the glomerulonephritis market.

    How is the global glomerulonephritis market divided into key segments?

    The glomerulonephritis market covered in this report is segmented –

    1) By Type: Acute Glomerulonephritis, Chronic Glomerulonephritis

    2) By Diagnosis: Urine And Blood Tests, Imaging Tests, Kidney Biopsy, Other Diagnosis

    3) By Treatment: Medication, Surgery, Dialysis, Other Treatments

    4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

    5) By End-User: Hospitals, Specialty Clinics, Other End-Users

    Subsegments:

    1) By Acute Glomerulonephritis: Post-infectious Glomerulonephritis, IgA Nephropathy, Lupus Nephritis, Rapidly Progressive Glomerulonephritis (RPGN), Goodpasture Syndrome

    2) By Chronic Glomerulonephritis: Focal Segmental Glomerulosclerosis (FSGS), Membranous Nephropathy, Minimal Change Disease, Alport Syndrome, Diabetic Nephropathy, Hypertensive Nephrosclerosis

    Get your free sample now – explore exclusive market insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21193&type=smp

    Who are the key firms paving the way for growth in the glomerulonephritis market?

    Major companies operating in the glomerulonephritis market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Asahi Kasei Medical Co. Ltd., Boehringer Ingelheim International GmbH, DaVita Inc., Biogen Inc., Merit Medical Systems Inc., Apellis Pharmaceuticals Inc., MorphoSys AG, Travere Therapeutics Inc., Vera Therapeutics Inc., Calliditas Therapeutics AB, Omeros Corporation, Otsuka Pharmaceutical Co. Ltd., Aurinia Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., NovelMed Therapeutics Inc.

    What key trends are currently impacting the glomerulonephritis market’s development?

    In the glomerulonephritis market, leading companies are striving to innovate and develop advanced non-immunosuppressive treatments to cater to unresolved medical demands and enhance patient recovery. Non-immunosuppressive treatments are the ones that neither downtrend nor suppress the immunity of a person and aim to treat conditions without affecting immune functionality. For example, in September 2024, a significant advancement was made by Travere Therapeutics Inc., a bio-pharmaceutical firm based in the US. They introduced FILSPARI (sparsentan), which got the approval of the Food and Drug Administration (FDA) for the treatment of IgA nephropathy, a type of kidney disease. This drug, being the sole non-immunosuppressive treatment, has been proven to considerably decelerate the decline of kidney functionality in these patients. FILSPARI’s approval signifies a significant milestone in managing IgA nephropathy, which is the most recurrent type of primary glomerulonephritis. With this therapy, a novel alternative has been made available to patients previously having only limited options. This approval emphasizes Travere’s dedication to enhancing patient outcomes dealing with kidney disease.

    Unlock exclusive market insights – purchase your research report now for a swift delivery!

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21193

    What regions are contributing significantly to the growth of the glomerulonephritis market?

    North America was the largest region in the glomerulonephritis market in 2024. The regions covered in the glomerulonephritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Browse Through More Similar Reports By The Business Research Company:

    Suture Laparoscopic Forceps Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/suture-laparoscopic-forceps-global-market-report

    Electrocautery Enhanced Delivery System Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/electrocautery-enhanced-delivery-system-global-market-report

    Anemia and Other Blood Disorder Drugs Global Market Report 2025

    https://thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Unlocking Opportunities in the Glomerulonephritis Market: Key Growth Trends and Forecast Insights

    Unlocking Opportunities in the Glomerulonephritis Market: Key Growth Trends and Forecast Insights

    Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

    What is the Growth Potential of the Glomerulonephritis Market, and How Will It Perform by 2034?

    In the last few years, the glomerulonephritis market has exhibited substantial growth. It’s projected to escalate from $11.06 billion in 2024 to $11.64 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.3%. This progression during the historic period was driven by factors such as the escalating incidence of kidney diseases, the widespread prevalence of infections like post-streptococcal glomerulonephritis, an uplift in research and development, a rise in kidney failure cases, and the enhanced awareness about kidney disorders.

    Expectations are high for substantial growth in the glomerulonephritis market in the coming years, with projections suggesting an escalation to $14.14 billion by 2029, at a compound annual growth rate (CAGR) of 5.0%. This anticipated growth during the forecast period can be attributed to several factors, including increasing rates of diabetes, an expanding older population, escalating investments in healthcare spending, a rise in the number of dialysis patients, and a surge in autoimmune disease cases. The forecast horizon also indicates significant trends, such as the introduction of innovative treatments and therapies, advancements in diagnostic technologies, new therapeutics and therapies, collaboration initiatives between industry companies, and the use of intravenous immunoglobulin therapy.

    Which Drivers Are Expected to Have the Greatest Impact on the Glomerulonephritis Market’s Growth?

    The glomerulonephritis market is anticipated to expand due to the increasing rate of kidney disorders. Such disorders encompass an array of conditions, impacting the kidneys’ structure or function, and result in compromised filtration, waste elimination, and fluid regulation. A surge in kidney disorders can be attributed to factors like an aging demographic, growing instances of chronic diseases such as diabetes and hypertension, and lifestyle decisions. These disorders lead to glomerulonephritis through provoking immune system anomalies, persistent inflammation, or structural harm, leading to hindered kidney filtration and function. For example, the Australian Institute of Health and Welfare, a government institution based in Australia, reported in December 2024 that chronic kidney disease (CKD) death rates rose by 4.2% in 2021 and 6.2% in 2022. Between 2021 and 2022, CKD accounted for about 2 million hospitalizations or 18% of all hospital stays in Australia. Hence, the escalating rate of kidney disorders is anticipated to fuel the glomerulonephritis market’s growth.

    Get Your Free Sample of the Global Glomerulonephritis Market Report Now!

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21193&type=smp

    Who Are the Major Companies Shaping the Competitive Landscape of the Glomerulonephritis Market?

    Major companies operating in the glomerulonephritis market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Asahi Kasei Medical Co. Ltd., Boehringer Ingelheim International GmbH, DaVita Inc., Biogen Inc., Merit Medical Systems Inc., Apellis Pharmaceuticals Inc., MorphoSys AG, Travere Therapeutics Inc., Vera Therapeutics Inc., Calliditas Therapeutics AB, Omeros Corporation, Otsuka Pharmaceutical Co. Ltd., Aurinia Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., NovelMed Therapeutics Inc.

    What Are the Key Emerging Trends in the Glomerulonephritis Market for the Next Decade?

    The glomerulonephritis market is witnessing leading businesses prioritise the creation of progressive non-immunosuppressive therapies to address medical needs that are currently unserviced and enhance patient outcomes. Non-immunosuppressive treatments, which do not compromise or reduce the strength of the immune system, are used to treat diseases without affecting immune activities. For instance, in September 2024, Travere Therapeutics Inc., a biopharmaceutical business based in the US, launched FILSPARI (sparsentan). This drug, endorsed by the Food and Drug Administration (FDA), is used for managing IgA nephropathy, a kidney-related disease. FILSPARI has proven to be the sole non-immunosuppressive treatment that noticeably slows down the worsening of kidney functioning in patients. This validation of FILSPARI denotes a significant step forward in treating IgA nephropathy, which has the highest incidence rate among primary glomerulonephritis. This therapy creates a new alternative for patients who previously had only a few options. This endorsement underscores Travere’s dedication to enhancing results for patients with kidney disease.

    Get Instant Access to the Global Glomerulonephritis Market Report with Swift Delivery!

    https://www.thebusinessresearchcompany.com/report/glomerulonephritis-global-market-report

    What Are the Core Categories and Segments in the Glomerulonephritis Market Driving Demand and Growth?

    The glomerulonephritis market covered in this report is segmented –

    1) By Type: Acute Glomerulonephritis, Chronic Glomerulonephritis

    2) By Diagnosis: Urine And Blood Tests, Imaging Tests, Kidney Biopsy, Other Diagnosis

    3) By Treatment: Medication, Surgery, Dialysis, Other Treatments

    4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

    5) By End-User: Hospitals, Specialty Clinics, Other End-Users

    Subsegments:

    1) By Acute Glomerulonephritis: Post-infectious Glomerulonephritis, IgA Nephropathy, Lupus Nephritis, Rapidly Progressive Glomerulonephritis (RPGN), Goodpasture Syndrome

    2) By Chronic Glomerulonephritis: Focal Segmental Glomerulosclerosis (FSGS), Membranous Nephropathy, Minimal Change Disease, Alport Syndrome, Diabetic Nephropathy, Hypertensive Nephrosclerosis

    Which Regions Are Making a Mark in the Glomerulonephritis Market Growth?

    North America was the largest region in the glomerulonephritis market in 2024. The regions covered in the glomerulonephritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    How Is the Glomerulonephritis Market Categorized and Defined in the Industry?

    Glomerulonephritis is a kidney disorder characterized by inflammation of the glomeruli, the tiny filters in the kidneys that remove waste and excess fluids from the blood. It can result from infections, autoimmune diseases, or other underlying conditions, leading to symptoms such as blood in urine, proteinuria, and swelling. If left untreated, it may progress to chronic kidney disease or kidney failure.

    Browse Through More Similar Reports By The Business Research Company:

    Suture Laparoscopic Forceps Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/suture-laparoscopic-forceps-global-market-report

    Electrocautery Enhanced Delivery System Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/electrocautery-enhanced-delivery-system-global-market-report

    Anemia and Other Blood Disorder Drugs Global Market Report 2025

    https://thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on: